Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Nervous system disorders – page 43

  • 1 389 clinical trials
  • 585 recruiting
  • 453 conditions
  • 29 countries

Conditions in this area

453 conditions with trials, the busiest first

Dementia Alzheimer's type87Multiple sclerosis59Parkinson's disease56Ischaemic stroke52Migraine48Myasthenia gravis43Glioblastoma40Amyotrophic lateral sclerosis31Duchenne muscular dystrophy28Neuroblastoma26Relapsing multiple sclerosis21Glioma20Relapsing-remitting multiple sclerosis20Narcolepsy19Cognitive disorder18Epilepsy18Giant cell arteritis18Partial seizures18Chronic inflammatory demyelinating polyradiculoneuropathy17Spinal muscular atrophy17Anaesthesia16Subarachnoid haemorrhage16Autism spectrum disorder15Insomnia15+429

Clinical trials in Nervous system disorders

1 389 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 389 clinical trials

Dementia+5

Recruiting

Study on the Benefits of Amyloid PET Imaging with Florbetaben (18F) and Flutemetamol (18F) for Patients with Various Types of Dementia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Florbetaben (18F)
  • Sponsor:Deutsches Zentrum Fuer Neurodegenerative Erkrankungen e.V.

Tourette's disorder

Recruiting

Study on Impulsivity Control in Adults with Tourette Syndrome Using [18F]-Altanserin and Aripiprazole

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Aripiprazole
  • Sponsor:Hospices Civils De Lyon

Kearns-Sayre syndrome

Recruiting

Study on the Effects of Calcium Folinate in Patients with Kearns-Sayre Syndrome and Cerebral Folate Deficiency

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:ANHYDROUS CALCIUM FOLINATE
  • Sponsor:Universitaetsmedizin Goettingen

Anti-myelin-associated glycoprotein associated polyneuropathy

Recruiting

Study on Zanubrutinib and Rituximab for Patients with IgM Monoclonal Gammopathy and MAG Antibodies-Related Polyneuropathy

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Zanubrutinib
  • Sponsor:Universitair Medisch Centrum Utrecht

Parkinson's disease

Recruiting

Study on Montelukast for Slowing Parkinson's Disease Progression in Patients with Mild to Moderate Symptoms

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Levodopa
  • Sponsor:Karolinska University Hospital

Pelizaeus-Merzbacher disease

Recruiting

Study on the Safety and Effects of ION356 for Patients with Pelizaeus-Merzbacher Disease

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:2'-O-(2-Methoxyethyl) Modified Antisense Oligonucleotide Targeting Plp1 Pre-Mrna
  • Sponsor:Ionis Pharmaceuticals Inc.

Glioblastoma

Recruiting

Study on Glioblastoma Recurrence: Comparing SonoCloud-9 with Carboplatin to Standard Treatments Lomustine or Temozolomide for Patients Undergoing Tumor Removal Surgery

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Carthera

Myasthenia gravis

Recruiting

Study on Zilucoplan Sodium for Children Aged 2 to 17 with Generalized Myasthenia Gravis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:ZILUCOPLAN
  • Sponsor:UCB Biopharma

Glioblastoma

Recruiting

Study on Perampanel Treatment Before Surgery for Patients with Progressive Glioblastoma

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Perampanel
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Duchenne muscular dystrophy

Recruiting

Efficacy and Safety of Givinostat for Non-Ambulant Patients with Duchenne Muscular Dystrophy

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Givinostat
  • Sponsor:Italfarmaco S.p.A.

Myasthenia gravis

Recruiting

Study on the Long-Term Safety of Zilucoplan in Children with Generalized Myasthenia Gravis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:ZILUCOPLAN
  • Sponsor:UCB Biopharma

Hypersomnia

Recruiting

Study on Melatonin and Light Therapy for Adults with Idiopathic Hypersomnia

Investigational
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Melatonin
  • Sponsor:Les Hopitaux Universitaires De Strasbourg

Substances studied in this area

The therapies tested most often in Nervous system disorders trials.

Sodium Chloride72 clinical trialsTemozolomide37 clinical trialsOcrelizumab33 clinical trialsRituximab27 clinical trialsCyclophosphamide25 clinical trialsParacetamol24 clinical trialsCarboplatin15 clinical trialsMethylprednisolone15 clinical trialsPrednisolone15 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.